From an Enterprise to an Era

May 19 – 20, 2022 • Ritz-Carlton Laguna Niguel, Dana Point, CA

2022 Speakers

Headshots and biographical descriptions of speakers for the 16th Annual Personalized Medicine Conference are presented below.

Amy P. Abernethy, M.D., Ph.D.

President, Clinical Studies Platforms


Amy P. Abernethy, M.D., Ph.D. is the President of Clinical Studies Platforms at Verily, an Alphabet company founded at the convergence of healthcare, data science and technology, where she has responsibility for the company’s Baseline program and other initiatives to support a broad range of clinical trials and real-world evidence (RWE) studies.

Before joining Verily in July, Dr. Abernethy was Principal Deputy Commissioner and Acting Chief Information Officer of the US Food & Drug Administration. While at the FDA, she initiated critical efforts including FDA’s technology and data modernization action plans and FDA’s efforts to leverage real-world data and evidence to address urgent questions during the COVID-19 pandemic. 

Dr. Abernethy was Chief Medical Officer and Chief Scientific Officer at Flatiron Health from 2014 to early 2019. Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine, and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. 

Dr. Abernethy went to the University of Pennsylvania as an undergraduate, and then medical school at Duke, where she also did her Internal Medicine residency, a year as Chief Resident, and her hematology/oncology fellowship. She has her Ph.D. from Flinders University in Australia, focused on evidence-based medicine.

Edward Abrahams, Ph.D.


Personalized Medicine Coalition

Edward Abrahams, Ph.D., is the President of PMC. Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.

Previously, Dr. Abrahams was the Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.

The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has taught history and public policy at Brown University and the University of Pennsylvania.


Lisa Alderson

Co-Founder, CEO

Genome Medical

Lisa Alderson is the CEO and Co-Founder of Genome Medical, Inc., a digital health company and nationwide telegenomics medical group, is transforming the delivery of medicine by enabling access to genomic-based medicine for everyday care. Through its nationwide network of genetic specialists and efficient Genome Care DeliveryTM technology platform, Genome Medical provides health expertise throughout the genomics journey.

Prior, Ms. Alderson served as the Chief Commercial Officer and Chief Strategy Officer of Invitae, a rapidly growing genetic information company. She was also the former CEO and president of CrossLoop Inc., a marketplace for technical services (acquired by Nasdaq: AVG). Prior to that, she was part of the start-up team at Genomic Health Inc. (Nasdaq: GHDX), president of Cinema Circle Inc., (acquired by Nasdaq: GAIA) and the former manager of strategic planning at The Walt Disney Co. Lisa also serves on the board of the Kidney Cancer Association. She has a track record of creating, funding, and managing high-growth ventures.

Lisa has an MBA with distinction from Harvard Business School and a B.A. from Colorado State University, where she graduated Summa Cum Laude.

Michael Andreini

President, CEO

Multiple Myeloma Research Foundation

Michael Andreini is the President and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC). Michael brings nearly 15 years of strategic consulting and operational experience in the life sciences industry. Prior to joining the MMRF, Michael was an Associate Principal at IQVIA in the consulting services organization, where he developed strategies for biopharmaceutical, medical device, and nonprofit organizations to drive innovation and operational excellence across a diverse set of business challenges including R&D and launch strategy, commercial due diligence and portfolio optimization, and organizational effectiveness. Before joining IQVIA, Michael worked at Fuld & Company, a boutique consulting firm specializing in competitive intelligence and strategy.

Cynthia A. Bens

Senior Vice President, Public Policy

Personalized Medicine Coalition

Cynthia A. Bens, Senior Vice President for Public Policy at the Personalized Medicine Coalition, leads the Coalition’s policy development and government relations efforts and serves as its primary liaison with the U.S. Congress and federal regulators. In collaboration with PMC’s Senior Vice President for Science Policy Daryl Pritchard, Ph.D., Bens is responsible for implementing research, regulatory, and reimbursement policy strategies that promote the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and the health system.

Before joining PMC, Bens was the Vice President of Public Policy at the Alliance for Aging Research. Bens guided the Alliance’s federal policy work, represented the organization in multiple national coalitions, and directed all aspects of coalitions led by the Alliance. She spent more than a decade at the Alliance advancing policies to expedite the development of interventions for neurological diseases and physical frailty; to remove access barriers for cardiovascular disease treatments; and to enhance the quality of care for older adults living with multiple chronic conditions.

Prior to joining the Alliance, Bens was a Senior Manager of Government Affairs with the Loeffler Group. As part of its federal government affairs practice, she represented client interests before the U.S. Congress and the administration. Her core areas of focus included appropriations, budget, health care, education, telecommunications and international trade. Through various other positions on Capitol Hill and in the private sector, she has acquired extensive experience researching and analyzing federal legislation and regulations.

Burns C. Blaxall, Ph.D.

Director, Precision Medicine

The Christ Hospital Health Network

Burns C. Blaxall, Ph.D., is the founding Executive Director of Precision Medicine at The Christ Hospital Health Network (TCHHN). He leads a transition from reactive to proactive healthcare delivery by harnessing the power of personal diagnostic and genomic data. Using approaches ranging from cutting-edge hereditary disease risk assessment, genetic counseling, and testing, to pharmacogenomics and genome-guided clinical care pathways, Precision Medicine at TCHHN aims to provide proactive, individualized care for every patient.

Dr. Blaxall received his Ph.D. in Pharmacology from the University of Colorado Health Sciences Center, followed by a postdoctoral fellowship at Duke University Medical Center. He held faculty positions at the University of Rochester Medical Center as well as at The University of Cincinnati and Cincinnati Children’s Hospital Medical Center, where he was Professor and founding Director of the Center for Translational Fibrosis Research, as well as Director of Translational Science and of the Heart Institute Clinical Research Core and Biorepository. He holds several patents, has published nearly 100 peer-reviewed manuscripts, and has received numerous honors, including the Early Career Investigator Award and the Outstanding Achievement Award from the American Heart Association; most recently he was highlighted among the top six regional healthcare innovators by Cincinnati Magazine, and was nominated as a Cincinnati Healthcare Hero. He has held extensive national and international leadership positions in numerous professional societies, chaired NIH peer-review panels, and serves on the editorial board for numerous top professional journals. He is an elected fellow of several professional organizations (ACC, AHA, ISHR, APS) and currently serves in national leadership and advocacy positions for prominent professional societies in the fields of Precision Medicine and Pharmacogenomics.

Fluent in Spanish (and some French), Dr. Blaxall has over 25 years of dedication to, and demonstrated success with, recruitment, development and retention of minority and underrepresented populations.

Randy Burkholder

Vice President, Policy and Research


Randy Burkholder is the vice president of policy and research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Burkholder leads PhRMA’s work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered health care, including payment and delivery reform, quality measurement, appropriate use and patient adherence, evidence-based medicine and health technology assessment, value of innovation, and personalized medicine.

Burkholder represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, the Centers for Medicare and Medicaid Services’ Technical Expert Panel on oncology, and the Federal Coordinating Council for Comparative Effectiveness Research. He is also a member of the board of directors of the Personalized Medicine Coalition and serves on the steering committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer Initiative.

Alex J. Carlisle, Ph.D.

Founder, Chairman, CEO

National Alliance Against Disparities in Patient Health

Dr. Alex Carlisle holds a doctorate in biochemistry and molecular biology from Howard University and has spent the past 17 years developing and applying translational and clinical research approaches in the areas of molecular oncology and neuroscience. Dr. Carlisle received his post-doctoral training at the U.S. National Institutes of Health, where he served at the National Cancer Institute as a leading member of the Cancer Genome Anatomy Project, and at the National Institute for Neurological Disorders and Stroke.

Kelly E. Caudle, Ph.D., Pharm.D.

Principal Investigator, Director

Clinical Pharmacogenetics Implementation Consortium (CPIC), St. Jude Children’s Research Hospital

Kelly E. Caudle, Pharm.D., Ph.D., BCPS is the Clinical Pharmacogenetics Implementation Consortium (CPIC) Principal Investigator and Director. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. To date, CPIC has published 24 gene-based clinical guidelines. Dr. Caudle oversees all CPIC-related projects and the CPIC guideline development process including the coordination of the guideline writing committees, the guideline evidence reviews, and the writing of the guideline manuscript and supplement. Furthermore, Dr. Caudle is involved in the clinical implementation of pharmacogenetics at St. Jude Children’s Research Hospital.

Dr. Caudle received her Pharm.D. and Ph.D. from The University of Tennessee Health Science Center and completed an ASHP-accredited PGY2 residency at Le Bonheur Children’s Hospital. She is also a board‐certified Pharmacotherapy Specialist. Dr. Caudle is currently an affiliate Assistant Professor at The University of Tennessee Health Science Center.

Kevin Conroy

CEO, President, Chairman of the Board

Exact Sciences

Kevin Conroy is the Chief Executive Officer, President, and Chairman of the Board of Exact Sciences. He became CEO 11 years ago and he has been part of a team that transformed Exact Sciences into one of the world’s premier cancer diagnostics companies with more than 4,500 employees.

Mr. Conroy has led Exact Sciences through the development, clinical trial, regulatory approval, and commercialization of its noninvasive colorectal cancer screening test, Cologuard®. This culminated with Cologuard becoming the first medical device or diagnostic to receive simultaneous FDA approval and national Medicare coverage. Since 2014, millions of Americans have used Cologuard to screen for colorectal cancer, the second leading cause of cancer death in the United States.

In 2019, Exact Sciences’ acquisition of Genomic Health united two of the industry’s strongest brands, Cologuard and Oncotype DX®, and established the company’s position as the global leader in advanced cancer diagnostics. The global company is working to improve screening, early detection, and treatment guidance throughout the cancer continuum.

Stephen L. Eck, M.D., Ph.D.

Senior Vice President, Clinical Development, Chief Medical Officer


Stephen Eck, M.D., Ph.D., Senior Vice President, Clinical Development & Chief Medical Officer, joined us in July 2020. Prior to MacroGenics, Dr. Eck served as chief medical officer of Immatics US, a company focused on TCR-based immunotherapies, and as president and chief executive officer of Aravive Biologics. Prior to these roles, Dr. Eck was Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma, managing a portfolio of assets which included enzalutamide (Xtandi®), erlotinib (Tarceva®) and gilteritinib (Xospata®). Dr. Eck has also held leadership positions in drug development as Vice President of Translational Medicine and Pharmacogenomics at Eli Lilly and as Head of Clinical Oncology at Pfizer. He began his professional career at Monsanto in cancer target discovery and later joined the University of Pennsylvania, where he was the Anne B. Young Assistant Professor of Cancer Research and the Director of the Cancer Gene Therapy Program. Dr. Eck currently serves as a director for Luminex Corporation (NASDAQ: LMNX) and Circulogene, and on the boards of directors for the Personalized Medicine Coalition and the Central Pennsylvania Clinic. He is also a fellow of the American Association for the Advancement of Science. Dr. Eck holds a B.A. from Kalamazoo College, an M.S. and a Ph.D. from Harvard University, and an M.D. from the University of Mississippi School of Medicine with Residency and Fellowship training at the University of Michigan.

Okan Ekinci, M.D.

Senior Vice President, Global Head of Marketing and Innovation

Roche Diagnostics Information Solutions

Okan is the Chief Medical Officer in Roche DIS, an organization focused on decision support solutions, powered by aggregated data and advanced analytics, in support of Roche’s personalized healthcare (PHC) strategy. He brings along 20 years of experience in the healthcare sector, among which eight years of clinical practice in cardiology. With his global team, he designs and implements novel value-centric approaches in medical and scientific affairs to support the whole lifecycle of digital health products & services – from early ideation and development through implementation and evidence generation.

Okan worked previously at Siemens Healthineers, where he was most recently Global Head of the Healthcare Consulting business, a unit developing and offering digitally-enabled transformation and clinical consulting services. Prior to that he established the Global Medical Office of Healthineers and served as its first CMO.

He is an adjunct professor of medicine at University College Dublin Medical School, Ireland.

Okan holds an MBA from the European School of Management and Technology, Berlin, Germany, and an MD from the University of Mainz, Germany.

Jami Elliott

Director, Global Business Development

Thermo Fisher Scientific

Jami Elliott leads clinical business strategy within Thermo Fisher Scientific’s Genetic Sciences Division (GSD) where he directs new platform & test development for diagnostic segments. Jami is actively involved in CE-IVD and U.S.-IVD strategy development; as well as programs focused on Pharmacogenetics enabled medication therapy management, reimbursement and regulatory strategy.

Lori Frank, Ph.D.

Senior Vice President, Research, Policy, and Programs, The New York Academy of Medicine; Medical, Scientific, and Memory Screening Advisory Board Member, Alzheimer's Foundation of America

Lori Frank is Senior Vice President, Research, Policy, and Programs, at The New York Academy of Medicine. Her current work is focused on methods for incorporating the consumer perspective into health outcomes research and healthcare valuation.

She is currently president of the International Society for Quality of Life Research, and she serves on the Board of the Personalized Medicine Coalition and the Alzheimer’s Foundation of America Medical, Scientific, and Memory Screening Advisory Board. She completed her Health and Aging Policy Fellowship through the American Political Science Association Congressional Fellowship Program with a placement at the National Institutes of Health.

Frank founded and served as program director of the Evaluation and Analysis Program at the Patient-Centered Outcomes Research Institute (PCORI), establishing a research program to examine stakeholder engagement, along with survey research and portfolio analysis functions. Prior to joining PCORI she served as executive director and senior research leader, Center for Health Outcomes Research, with MEDTAP International/United BioSource Corporation, where she managed the scientific and financial performance of the Center, overseeing international operations.

Her career has focused on patient-reported outcomes measure development and assessment. She has held research and teaching positions with Georgetown University Department of Psychiatry, the National Institute on Aging, Medimmune LLC/AstraZeneca, and the Veteran’s Administration. She completed postdoctoral training in mental health services research with the VA Health Services Research and Development program and Department of Psychiatry. She holds a Ph.D. in human development/gerontology from the Pennsylvania State University and an M.A. in biopsychology from the Johns Hopkins University.

J. Michael Graglia

Co-Founder, Managing Director

SynGAP Research Fund

Mike comes from a career in public policy, international development and strategy.  Previous roles have included establishing a new program at New America, a DC think tank, Budget & Planning at both the Gates Foundation & Emerson Collective, healthcare consulting at BCG, developing world university support for the World Bank Group, managing a refugee program for the International Catholic Migration Commission in Zimbabwe, and teaching math in Peace Corps Namibia.

Graglia has an MBA from Columbia University where he was a Bronfman Fellow, an MA in Southeast Asian studies from Johns Hopkins School of Advanced International Studies where his studies were supported by the Paul & Daisy Soros Fellowship for New Americans. He studied mathematics at Gonzaga University, S.J.

Jill Hagenkord, M.D.

Chief Medical Officer

Optum Genomics

Jill Hagenkord, M.D., is the Chief Medical Officer of Optum Genomics. Dr. Hagenkord is a board-certified pathologist with subspecialty boards in molecular genetic pathology and an additional fellowship in pathology/oncology informatics. She specializes in the development, validation, and implementation of novel health technologies as well as coding, coverage, and reimbursement issues for novel tests.

Prior to joining Optum, she was the Chief Medical Officer of several Silicon Valley genomic companies, including Invitae and 23andMe. She began her career as the Director of Molecular Pathology and Assistant Professor of Pathology at Creighton University School of Medicine. Dr. Hagenkord is active in the College of American Pathologists, the Association for Molecular Pathology, the American College of Medical Genetics and Genomics, and the National Academy of Medicine’s Genomics and Precision Health Roundtable. She lives in suburban Des Moines with her teenage sons, two dogs, and two cats.

William Hagstrom

Founder, CEO

Octave Bioscience

William Hagstrom has over 30 years of start-up experience in a broad range of medical specialties integrating new science, technology, and data analytics to improve patient outcomes. Prior to founding Octave Bioscience, he was CEO of Crescendo Bioscience, which created novel measurement tools and software in rheumatology. Previously, he was President of Alpha BioPartners, a strategic consulting firm focused on launching new life sciences companies, where he created the business plan for Crescendo and co-founded Altheus Therapeutics and Biolytx Pharmaceuticals.

Prior to that, he was the initial CEO of Selexys Pharmaceuticals and interim CEO of Inoveon in ophthalmology. In the 1990s, Bill was Chairman and CEO of UroCor, a urology specialty diagnostics company that he scaled from start-up through IPO. Earlier, he was Vice President of Baxter International’s $1 billion Scientific Products Division and held management positions at American Hospital Supply and Becton Dickinson.

Bill currently serves on the boards of directors for CareDx and CoFactor. Previously, he was on the board of Prometheus Laboratories. Bill holds a B.S. in business management from Bob Jones University.

Megan P. Hall, Ph.D.

Vice President, Medical Affairs


Megan P. Hall is Vice President of Medical Affairs at GRAIL, where she established and leads the Medical Affairs group supporting the development and launch of Galleri, a blood-based multi-cancer early detection test. Previously, Megan was Director of Medical Communications at Jazz Pharmaceuticals, where she led health care provider-focused publication and education strategies for the company’s hematology/oncology and chronic pain portfolios. Before Jazz, Megan established a Medical Communication team at Natera to support the launch and evolution of the Panorama non-invasive prenatal test, and was an editor at the flagship open access journal, PLOS Biology. She also held research roles funded by the American Heart Association, the California Institute of Regenerative Medicine, the National Institutes of Health, and the Howard Hughes Research Foundation.

Megan earned a B.S. in biological sciences from the University of California at Santa Barbara and a Ph.D. in microbiology, immunology, and molecular genetics from the University of California at Los Angeles.

Richard Hamermesh, D.B.A.

Co-Faculty Chair

Harvard Business School Kraft Precision Medicine Accelerator

Richard Hamermesh is a Senior Fellow at the Harvard Business School, where he was formerly the MBA Class of 1961 Professor of Management Practice. Currently, Richard is the Faculty Co-Chair of the Kraft Precision Medicine Accelerator. Richard created and teaches the second-year MBA elective, Building Life Science Businesses. Previously, he was the course head for the required first-year course, The Entrepreneurial Manager.

From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. Prior to this, from 1976 to 1987, he was a member of the faculty of the Harvard Business School.

Richard is also an active investor and entrepreneur, having participated as a principal, director and investor in the founding and early stages of more than 20 organizations. He was the founding president of the Newton Schools Foundation and served on the editorial board of the Harvard Business Review.

Richard is the author or co-author of five books, including New Business Ventures and The Entrepreneur. His best-known book, Fad-Free Management, was published in 1996. He has published more than 100 case studies and numerous articles, including his recent publications “What Precision Medicine Can Learn from the NFL” and “One Obstacle to Curing Cancer: Patient Data isn’t Shared.”

Kate Haviland

President, CEO

Blueprint Medicines

Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, commercial and strategic planning, and program management. Prior to becoming Blueprint Medicines’ CEO, Kate served as its Chief Operating Officer and as its Chief Business Officer. Over this time, she served as the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including portfolio strategy, corporate development, commercial strategy, international, technical operations, corporate affairs, and information systems.

Thomas C. Hawes, M.D.

Partner; Member

Sandbox Industries; BlueCross BlueShield Fund Management Team

Tom Hawes is a member of the BlueCross BlueShield Fund Management team at Sandbox Industries. He serves on the Board of Directors of Owl Insights, Upward Health, Octave Bioscience, OncoHealth, and Perspectum. He is a former Board Member of Patientco (Waystar), Verata Health (, AbleTo (Optum), HeartFlow, Phreesia (NYSE: PHR), Nexidia (NICE), IVL (HCA), Healthify (Wellsky), and Board Observer at Thrive (Acq by Exact Sciences Nasdaq: EXAS). Tom holds a BA from Brigham Young University, an M.D. from New York Medical College, medical residency at Yale, and an MBA from Harvard Business School. He is also a Kauffman Fellow.

Colin Hill

Chairman, CEO, Co-Founder

GNS Healthcare

Colin Hill is a leading voice in healthcare technology and precision medicine and brings impressive leadership experience in commercializing machine learning technologies in the biopharmaceutical and managed care industries. He co-founded GNS Healthcare, a leading AI-driven precision medicine company, in 2000 and has since served as Chairman & CEO. In 2020 the company launched Gemini, the in silico patient, a highly accurate computer model of disease.

Colin sits on the board of Biotelemetry Inc., the leading mobile health information company, and PPD, a leading global contract research organization. He is also a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation (501c3) dedicated to the advancement of personalized medicine. In 2016, he was appointed by Massachusetts Governor Charlie Baker to the Massachusetts Digital Health Council.

Colin was a founding member of the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease (acquired by Baxter in 2014), and he was the founding chairman of O’Reilly Media’s Strata Rx in 2012, the first healthcare big data conference in the industry.

Laura Holmes Haddad

Writer, Patient Advocate

Laura Holmes Haddad is a writer, patient advocate, and speaker from Massachusetts. A former cookbook editor and food writer, Laura’s career focus shifted when she was diagnosed with Stage IV inflammatory breast cancer at the age of 37.

After completing three years of precision medicine-based treatment—including a Phase 1a clinical trial—Laura remains NED and speaks to a wide range of audiences about cancer-related topics. Her speaking engagements have included panels and keynotes to various stakeholders, including patients, providers, payers, and legislators. She shares her insights on topics such as clinical trials; financial side effects; hereditary cancer and genetic testing; and parenting with cancer. Her advocacy work is rooted in healthcare policy reform for access to comprehensive cancer care.

Laura has contributed articles related to cancer and health to numerous publications and has been a guest on numerous radio shows and podcasts to discuss cancer issues. She is also the author of This is Cancer: Everything You Need to Know, from the Waiting Room to the Bedroom (Hachette/Seal Press), where she writes frankly about the patient experience and shares practical tips and resources for getting through a cancer diagnosis.

Kris Joshi, Ph.D.

Executive Vice President; President, Network Solutions

Change Healthcare

Mr. Joshi is Executive Vice President and President, Network Solutions for Change Healthcare. He initially joined Change Healthcare as Executive Vice President, Products in December 2013. Prior to that, Mr. Joshi was Global Vice President for health care product strategy for the Health Sciences Global Business Unit of the Oracle Corporation. He helped launch the health sciences business unit and successfully led two acquisitions for Oracle in the life sciences space. Before joining Oracle, Mr. Joshi served in senior strategy roles in IBM’s Global Sales and Distribution organization. Prior to that, Mr. Joshi was with McKinsey and Company, where he served Fortune 500 clients on strategy issues.

Mr. Joshi holds a Bachelor’s degree in mathematics from Caltech, and a Ph.D. in physics from MIT.

Carl June, M.D.

Richard W. Vague Professor in Immunotherapy

University of Pennsylvania

Carl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston, 1979. He had graduate training in immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland, from 1978 – 1979, and post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 – 1986. He is board certified in internal medicine and medical oncology.

Richard Knight


American Association of Kidney Patients

Richard Knight received his MBA from the University of Virginia Darden School of Business and his B.A. from Hampton University. He is a results-oriented business strategist with diverse experience in public and private sectors in Finance, Accounting, Business Development, Healthcare, and Non-Profits. Entrepreneurial experience includes starting and running several ventures. Currently, he is a business strategist, providing patient engagement consulting for healthcare organizations and businesses developing tools designed to leverage patient input and preferences in their care plans and quality measures. He serves as an adjunct professor at Bowie State University (BSU). He is a founding member of BSU’s College of Business Advisory Council.

Mr. Knight is a healthcare professional and a former hemodialysis patient. He received a kidney transplant approximately fourteen years ago. He is President of the American Association of Kidney Patients (AAKP), which is the oldest and largest independent kidney patient organization in the United States.

Clifton Leaf

Global Fellow

Ellison Institute for Transformative Medicine

Clifton Leaf is a Global Fellow at the Ellison Institute for Transformative Medicine and an Adjunct Professor of Journalism at Columbia University’s Graduate School of Journalism. Previously (until June 2021) he was the 19th Editor-in-Chief of FORTUNE, where he directed the editorial content and strategy across all of FORTUNE’s platforms, shepherding this venerable publication through its 90th anniversary and beyond. During his nearly four-and-a-half-year tenure as Editor-in-Chief, FORTUNE was honored with more than 70 top journalism prizes, earned high acclaim for its print magazine redesign, substantially expanded its digital offerings, audience, and virtual events, and built a formidable premium subscription business. Previously, he served as Deputy Editor of FORTUNE for three years, overseeing the print magazine, and before that was a guest editor for the New York Times op-ed page and Sunday Review. Earlier in his magazine career, he was Executive Editor both at the Wall Street Journal’s SmartMoney magazine and at FORTUNE.

He is also the author of the critically acclaimed book, The Truth in Small Doses: Why We’re Losing the War on Cancer—and How to Win It, which was named by Newsweek as one of “The Best Books About Cancer,” and which earned Cliff a Lifetime Achievement Award for cancer reporting from the European School of Oncology. A winner of the Gerald Loeb Award for Distinguished Business and Financial Journalism, the NIHCM’s Health Care Journalism Award, and a two-time finalist for the National Magazine Award, Cliff has received numerous leadership honors for his efforts in the cancer fight, including the Ribbon of Hope from the National Coalition for Cancer Survivorship.

A member of the Board of Fellows at Stanford University School of Medicine and the advisory board for Harvard Public Health, Cliff has presented testimony to the President’s Cancer Panel three times and been a keynote speaker at more than three dozen scientific conferences around the world. In 2006, he delivered “Grand Rounds” at the National Cancer Institute, making him the first and, to this day, only journalist to have received that honor.

Peter Maag, Ph.D.

Board Member


Dr. Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Peter was President of Novartis Diagnostics. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Peter also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically-growing and emerging market as Country President, Korea. At Novartis headquarters in Switzerland, he served as the Head of Strategy for Novartis Pharmaceuticals and helped launch the Infectious Diseases franchise. Prior to joining Novartis, Peter worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Besides supporting various healthcare and tech companies in their growth efforts, he holds a supervisory board position at Phoenix Pharma SE and serves on the board of the Personalized Medicine Coalition in Washington, DC. Peter studied pharmaceutical sciences in Heidelberg and London, and received his PhD from the University of Berlin, Germany.

Howard McLeod, Pharm.D.

Executive Clinical Director, Precision Health

Intermountain Healthcare

Dr. Howard McLeod is an internationally recognized expert in precision medicine, having made novel contributions at the discovery, translation, implementation, and policy levels. He is the Medical Director for Precision Medicine at the Geriatric Oncology Consortium and a Professor of Medicine and Pharmacy at the University of South Florida. Dr. McLeod chaired the NHGRI eMERGE network external scientific panel for the past decade and was a recent member of both the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. Dr. McLeod has been recognized as a Fellow of both the American Society of Clinical Oncology and the American College of Clinical Pharmacy and was recently ranked #1 USA/#2 World for Pharmacogenomics. He has also been an active Board Member and/or Founder for over a dozen privately held and publicly traded companies.  Howard has published over 580 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance innovative healthcare.

Tom Miller

Founder, Managing Partner

GreyBird Ventures

After earning a graduate degree from the Harvard/MIT Health Sciences and Technology program, Tom joined Siemens where he ran the global MRI business. He has also served as the CEO of the global medical operations of Carl Zeiss, the CEO of Analogic Corporation, and Chairman and CEO of LightLab Imaging, a start-up he helped to establish and sell. Tom re-joined Siemens in 2002 serving as a member of the Global Operating Board and Division CEO of Siemens Healthcare with 26,000 employees in over 130 countries. In 2013, Tom started GreyBird Ventures, an investment firm focused on technologies for precision medicine diagnosis. Tom is a speaker on healthcare technology at conferences around the world and serves as director on the boards of five medical technology companies.

Susanne Munksted

Chief Precision Officer


Susanne is responsible for leading the Knowledge And Insights Team of experts in Diaceutics. As the pharmaceutical business model continues to change towards precision medicine there is a need to think differently and in an integrated way about the pharmaceutical and diagnostic business models from the top down in organizations. As Chief Precision Officer, it is Susanne’s role to drive this agenda and help Diaceutics’ clients understand the critical relationship and dependency between testing and treatment and ultimately think precision medicine into corporate strategies and tactical plans.

Susanne has broad commercial experience with molecular pathology, where she has led several global launches of companion diagnostic products.

Lincoln Nadauld, M.D., Ph.D.

Vice President, Chief of Precision Health and Academics

Intermountain Healthcare

Lincoln Nadauld, M.D., PhD., is the Chief of Precision Health at Intermountain Healthcare.  Dr. Nadauld founded the Intermountain Precision Genomics program with a vision of finding solutions to improve health and disease through genomics and precision medicine without increasing costs.  With his vision in mind, he oversees the clinical implementation of Precision Genomics across Intermountain’s 24 hospitals and 160 physician clinics.  In addition, Dr. Nadauld facilitates genomic research to better understand the human genome.  Dr. Nadauld conceived of and is leading the recently announced Heredigene, Population Study.  A collaborative effort with deCODE Genetics in Iceland to collect and perform whole-genome sequencing on 500,000 participants in the Intermountain system.

Dr. Nadauld completed clinical training in Medical Oncology at Stanford University School of Medicine, where he also completed a postdoctoral fellowship in solid tumor genomics. He remains a visiting scholar at Stanford University, focusing on cancer genomics and personalized medicine. His work has been published extensively and featured in a case study by Harvard Business Review, which discusses Intermountain Precision Genomics’ cutting-edge cancer care approach. Dr. Nadauld participated in the Precision Medicine Initiative Summit and roundtables at the White House with former President Barack Obama. He also participated in former Vice President Biden’s Cancer Moonshot Summit. His work in founding Intermountain Precision Genomics was recognized with the Utah Governor’s 32nd Annual Science Medal for Industry. This medal is the highest civilian award to be bestowed by the state of Utah, honors significant contributions to science and technology.

Dr. Nadauld is married with five children and enjoys attending their many activities and events, water sports, fishing, and other athletic pursuits.

Robert Nussbaum, M.D.

Chief Medical Officer


Robert L. Nussbaum, MD is the Chief Medical Officer of Invitae. He is board certified in internal medicine, clinical genetics and clinical molecular genetics, and is a Fellow of the American College of Physicians and the American College of Medical Genetics and Genomics. From 2006-2015, he was the Holly Smith Professor of Medicine at UCSF, and Chief of the Division of Genomic Medicine.

Before that he served in the Division of Intramural Research of the National Human Genome Research Institute, NIH, and, before NIH, was a Professor of Human Genetics, Pediatrics and Medicine at the University of Pennsylvania and an Associate Investigator of the Howard Hughes Medical Institute. He received an M.D. in 1975 from the Harvard-MIT Joint Program in Health Science and Technology, internal medicine training at Barnes Hospital/Washington University (1975-1978), and genetics training at Baylor College of Medicine (1978-1981).

He is the co-author of 277 peer-reviewed publications in basic and applied human genetics as well as numerous commentaries, editorials, and textbook chapters. He was elected to the National Academy of Medicine (IOM) in 2004 and the American Academy of Arts and Sciences in 2015.

Dr. Nussbaum served as a member of the Board of Directors and President of the American Society of Human Genetics, on the Board of Directors of the American Board of Medical Genetics and Genomics, and was a founding fellow and a member of the Board of Directors of the American College of Medical Genetics and Genomics.

Elizabeth O’Day, Ph.D.

CEO, Founder


Elizabeth O’Day, M.Phil., Ph.D., is the CEO and Founder of Olaris, Inc., a precision medicine company that uses a pioneering metabolomics platform and proprietary machine learning algorithms to fundamentally improve how disease is diagnosed and treated. Olaris identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events, and reducing unnecessary healthcare costs.

Outside of Olaris, Dr. O’Day plays an incredibly active role in partnering with government leaders and global organizations in advancing the field of precision medicine around the world. Dr. O’Day was invited to attend the first United States of Women Summit convened by the White House in 2016 and was selected to participate in Vice President Joe Biden’s Cancer Moonshot Summit to discuss collaborative ways “to end cancer as we know it.” In 2016, Dr. O’Day began serving as the co-chair of the World Economic Forum’s Global Future Council on Biotechnology where she focuses on leading the council in identifying policy opportunities capable of accelerating new biotech discoveries, and guiding the dialogue about the implications of biotech advancements globally.

Dr. O’Day was recognized by Boston Business Journal as a 40 under 40 honoree in 2020. She is also on the Steering Committee and a contributor for Scientific American’s annual “Top 10 Emerging Technologies” and serves on the Personalized Medicine Coalition (PMC) Board of Directors.

Dr. O’Day earned her Ph.D. from Harvard University, where she was a National Science Fellow; an MPhil in Chemistry from the University of Cambridge where she was a Churchill Fellow; and a BS in Biochemistry from Boston College where she was a Finnegan Award winner, Beckman Scholar, and Goldwater Scholar.

Michael J. Pellini, M.D.

Managing Partner

Section 32

Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology and healthcare. Prior to joining Section 32 in 2017, he served as CEO and Chairman of Foundation Medicine, a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to chairman through the close of Roche’s acquisition of FMI in August 2018. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010.

He currently serves as a member of the Board of Directors for Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave BioSciences, Sema4, Cradle Genomics, TwinStrand Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). He previously served on the board of Thrive Earlier Detection, which was acquired by Exact Sciences  in January, 2021. Mike brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.

Since the early days of the pandemic, Mike has also been serving as a Senior Advisor to the Rockefeller Foundation’s efforts on COVID-19 testing.

Mike received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.

Daryl Pritchard, Ph.D.

Senior Vice President, Science Policy

Personalized Medicine Coalition

Daryl Pritchard, Ph.D., is the Senior Vice President of Science Policy at the PMC, where he leads PMC’s efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory and payment policies.

Before coming to PMC, Dr. Pritchard served as the Director of Policy Research at the National Pharmaceutical Council. Prior to joining NPC, he served as the Director of Research Programs Advocacy and Personalized Medicine at the Biotechnology Innovation Organization (BIO).

Dr. Pritchard received his Ph.D. and master’s degree in genetics from the George Washington University, and completed a post-doctoral research fellowship at the Children’s National Medical Center. He was awarded the first American Society of Human Genetics/NHGRI Fellowship in Genetics and Public Policy, where he worked as a health legislative assistant in the House of Representatives.

Dan M. Roden, M.D.

Senior Vice President for Personalized Medicine

Vanderbilt University Medical Center

Dan Roden was born and raised in Montreal, and received his medical degree and training in internal medicine from McGill University. He then went to Vanderbilt, where he trained in clinical pharmacology and cardiology, and has been a faculty member there since. His initial career focus — that he has maintained — was studies of the clinical, genetic, cellular, and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies.

Over the last 10 years, Dr. Roden has led Vanderbilt’s broader efforts in pharmacogenomics discovery and implementation. He is principal investigator for the Vanderbilt sites of the National Institutes of Health’s Pharmacogenomics Research Network (PGRN) and the National Human Genome Research Institute’s Electronic Medical Records and Genomics (eMERGE) Network. He directs the Vanderbilt DNA databank BioVU, a discovery resource that as of Spring 2014 included more than 175,000 samples linked to de-identified electronic medical records. He is a leader in Vanderbilt’s PREDICT project, which, since 2010, has pre-emptively embedded pharmacogenomic variant data in the electronic medical records of more than 14,000 Vanderbilt patients. As of April 2013, PREDICT displays information on five drug-gene pairs and delivers point-of-care decision support when a target drug is prescribed to patients with variant genotypes.

Don Rule

CEO, Founder

Translational Software

Don began his career at Dun & Bradstreet as a financial analyst and used his programming skills to advance to a position as Director of Management Information Systems for the networking division. During his 14-year career at Microsoft, he held a variety of program management positions including launch products for the Microsoft Network, Virtual Private Networking, and Real Time Communications as well as founding the BioIT Alliance. He founded Translational Software in 2009 to provide tools that enable clinicians to practice precision medicine.

Catherine Sanders, Ph.D.

Vice President, Research and Business Development

Adaptive Biotechnologies

Catherine Sanders, PhD, M.S., is Vice President, Research and Business Development at Adaptive Biotechnologies,  a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. With more than 10 years at the company and vast expertise in the field of immunosequencing, Catherine is responsible for establishing partnerships with pharmaceutical companies and collaborations with key opinion leaders in oncology, hematology, transplantation, infectious disease and autoimmunity to drive therapeutic development.

Catherine began her career as a post-doctoral fellow at the HudsonAlpha Institute for Biotechnology analyzing immune repertoire changes in cancer, autoimmune disease, and infectious disease.  She received a Ph.D. in immunopathology and a M.S. in pathology from the University of Mississippi Medical Center in Jackson where she focused on TLR, chemokine receptor, and cytokine expression in HIV-infected T lymphocyte subsets.  Catherine also holds a BS degree in Medical Technology from Mississippi State University and received her board certification from Vanderbilt University Medical Center.

Jeffrey A. Shaman, Ph.D.

Chief Science Officer

Coriell Life Sciences

Jeffrey A. Shaman, Ph.D., M.S., is the Chief Science Officer at Coriell Life Sciences where he oversees the company’s research, education, and clinical programs and leads efforts focused on bridging the gap between genetic science and clinical application. Dr. Shaman brings years of experience in advising cross-functional teams together with his scholarship in genetics, pharmacology, stem cells, and clinical laboratory operations. Along with the CEO, he forges strategic partnerships with worldwide companies, laboratories, academic institutions, public/private self-insured companies, and federal, state, and regional healthcare and employee systems.

Dr. Shaman supports a team of scientists dedicated to precision medicine and pharmacogenomics and who actively research, publish, and present findings in top-tier peer-reviewed journals. He is passionate about educating people from all backgrounds about the power of genetics and pharmacogenomic testing that is integrated with patient health history and clinical decision-support to proactively promote better health.

Dr. Shaman holds a doctoral degree from The Johns Hopkins University School of Medicine in Pharmacology and Molecular Sciences, where his research centered on DNA, epigenetics, and nuclear structure and function. He earned his Master of Science degree from The University of Medicine and Dentistry of New Jersey in Cell & Developmental Biology. Dr. Shaman held a faculty position at the University of Hawaii Institute of Biogenesis Research before serving a fellowship at Harvard Medical School and implementing a translational research program at Beth Israel Deaconess Medical Center and the Bedford Stem Cell Research Foundation.

Christi Shaw


Kite, a Gilead Company

Christi Shaw serves as Chief Executive Officer of Kite, Gilead’s cell therapy company. Based in Santa Monica, California, Christi and her team at Kite are pursuing the ambitious goal of curing cancer as an industry leader in CAR T-cell therapy. In her role, Christi is responsible for Kite’s end-to-end, global cell therapy business. She is driven by values, integrity and a deep connection to people living with cancer and those who love them. Her leadership has spanned a broad range of therapeutic areas, including oncology, immunology, Alzheimer’s disease, medical devices, and she has been responsible for overseeing the full lifecycle of product portfolios, from discovery and development to commercialization and manufacturing.

Before joining Kite, Christi held senior executive positions at Eli Lilly & Co. and Novartis Corp. Christi currently serves on the board of directors of Avantor and the Healthcare Businesswomen’s Association (HBA) and is on the executive committee and the board of directors of the Biotechnology Innovation Organization (BIO). Christi holds a bachelor’s degree in business administration from Iowa State University and an MBA from the University of Wisconsin. She resides with her husband and son in Santa Monica, California.

Michael Sherman, M.D.

Executive Vice President, Chief Medical Officer


Dr. Michael Sherman serves as Chief Medical Officer and Executive Vice President for Point32Health, which was created in early 2021 by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. He is widely recognized as a leader in partnering with precision medicine companies to develop innovative approaches to broadening access to innovative technologies while also generating real-world evidence that can drive change more broadly.

Dr. Sherman serves as chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, and on the Advisory Board of the Institute for Clinical and Economic Review (ICER). He also is the current chair for AHIP’s CMO Leadership Council, and serves on the board of directors for the Personalized Medicine Coalition, and on the board of advisors for the Harvard Business School Healthcare Initiative.

Prior to joining Harvard Pilgrim, Dr. Sherman served as corporate medical director, physician strategies for Humana, and he previously held leadership positions at UnitedHealth Group, Thomson Medstat (now IBM Truven), HealthAllies, which was purchased by UnitedHealth Group in 2003, Immusol, and Da Vita.

Dr. Sherman holds a B.A. in Anthropology and Natural Sciences and an M.S. in Biomedical Anthropology from the University of Pennsylvania. He received his M.D. from Yale and M.B.A. from the Harvard Business School. Dr. Sherman is a diplomate of the American Board of Anesthesiology and American Board of Medical Management.  In 2009, he was named a fellow of the American College of Physician Executives, and he currently serves on the faculty of the Department of Population Medicine at Harvard Medical School.

Lauren Silvis

Senior Vice President of External Affairs


Lauren Silvis serves as Senior Vice President of External Affairs, overseeing regulatory, public policy and government affairs. Silvis most recently served as the Chief of Staff of the U.S. Food and Drug Administration. Prior to that role, she was the Deputy Center Director for Policy in FDA’s Center for Devices and Radiological Health. At the FDA, she advanced policies on clinical testing, precision medicine, and digital health. Silvis was also a partner at Sidley Austin LLP, focusing on FDA regulation of pharmaceuticals and medical devices. She graduated from Duke University and earned her law degree from Georgetown University Law Center.

Jean-Charles Soria, M.D., Ph.D.

Senior Vice President, Research and Development


Jean-Charles Soria is Amgen’s senior vice president of oncology within global development. Soria joined Amgen from Instiut Gustave-Roussy, where he was appointed director general by France’s minister of health and solidarity.

Soria is a medical oncologist and professor of medicine at Paris-Saclay University. He holds a doctorate in molecular biology. He completed his training during a two-year appointment at the MD Anderson Cancer Center in Houston, Texas, where he was an associate professor from 2013 to 2017. He also served as the director of the Gustave-Roussy SIRIC Socrate (Integrated Cancer Research Site) from 2012 to 2017.

From 2017 to 2019, Soria held the role of senior vice president, research and development in oncology, with AstraZeneca in Gaithersburg, Maryland, where he led research teams responsible for strategy and for development of new agents in immuno-oncology, cell therapy, and conjugated antibodies. He has authored or co-authored more than 670 articles in leading international journals and has appeared on lists of the most influential research scientists in the world.

Mark P. Stevenson

Board Member

Personalized Medicine Coalition

Mark Stevenson served for five years as the Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific, with responsibility for all of Thermo Fisher’s life sciences-related businesses as well as the company’s innovation and digital strategy. He joined the company as Executive Vice President and President, Life Sciences Solutions, through the acquisition of Life Technologies in 2014.

Mark previously served as President and Chief Operating Officer of Life Technologies, and President and Chief Operating Officer of Applied Biosystems prior to its merger with Invitrogen Corporation in 2008.

Mark received his M.B.A. from Henley Management School in the U.K. and his bachelor’s degree in chemistry from the University of Reading, also in the U.K.

Apostolia M. Tsimberidou, M.D., Ph.D.


The University of Texas MD Anderson Cancer Center

Dr. Apostolia M. Tsimberidou (Tsimperidou) is an oncologist in Houston, Texas and is affiliated with University of Texas MD Anderson Cancer Center. She received her medical degree from Aristotle University of Thessaloniki School of Medicine and has been in practice for more than 20 years.

Jay G. Wohlgemuth, M.D.

Chief Medical Officer, Senior Vice President, Research and Development, Medical, Population Health

Quest Diagnostics

Jay G. Wohlgemuth, M.D., is Chief Medical Officer and Senior Vice President, Research & Development and Medical for Quest Diagnostics. Based at Quest Diagnostics Nichols Institute, in San Juan Capistrano, California, Dr. Wohlgemuth is responsible for Research & Development (R&D), Medical Affairs and Medical/Lab Quality. In addition, he is responsible for improving outcomes for employees who use Quest’s health benefits.

Dr. Wohlgemuth has many years of experience in medical diagnostics and research and development. He rejoined Quest in 2016 from HealthTap, a health information start-up, where he served as Senior Vice President and Chief Healthcare Officer. Prior to that, he was Senior Vice President, R&D, Medical and Chief Scientific Officer with Quest. Dr. Wohlgemuth originally joined Quest in 2009 from Genentech, where he was Director, Clinical Diagnostics, ITGR (Immunology, Tissue Growth and Repair) and Global Development Team Leader for Ocrulizumab. He also served as Vice President, Research and Development for VIA Pharmaceuticals and as Chief Medical Officer for the molecular diagnostics company XDx, a company he co-founded. In addition, Dr. Wohlgemuth served as Vice President, Research & Development for XDx. For his work at XDx he was awarded Technology Pioneer 2005 at the World Economic Forum in Davos. Received the C Everett Koop award for the best population health program in the US in 2020. He serves on the Board of Directors for the Diagnostic Labs of Oklahoma, The Anne and Henry Zarrow Charitable Foundation, and Personalized Medicine Coalition.

Dr. Wohlgemuth earned his bachelor’s degree in biology from Harvard College and his medical degree from Stanford University School of Medicine, where he also served a fellowship in cardiovascular medicine.

Janet Woodcock, M.D.

Principal Deputy Commissioner

U.S. Food and Drug Administration

The winner of the Personalized Medicine Coalition’s first Award for Leadership in Personalized Medicine in 2005, Janet Woodcock is the FDA’s Principal Deputy Commissioner. In this role she works closely with the Commissioner of Food and Drugs to develop and implement key public health initiatives and helps oversee the agency’s day-to-day functions.

She served as the Acting Commissioner of Food and Drugs from January 20, 2021, until February 17, 2022.

Dr. Woodcock began her FDA career in 1986 at the Center for Biologics Evaluation and Research (CBER). At CBER, she served as Director of the Division of Biological Investigational New Drugs and as Acting Deputy Director. She later became Director of CBER’s Office of Therapeutics Research and Review, which oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis during her tenure.

In 1994, Dr. Woodcock was named Director of the FDA’s Center for Drug Evaluation and Research (CDER), leading the Center’s work that is the world’s gold standard for drug approval and safety. There she conceived and implemented many of the FDA’s drug initiatives, including introducing the concept of risk management as a new approach to drug safety; modernizing drug manufacturing and regulation through the Pharmaceutical Quality for the 21st Century Initiative; advancing medical discoveries from the laboratory to consumers more efficiently under the Critical Path Initiative; launching the Safety First and Safe Use initiatives designed to improve drug safety management within and outside the FDA, respectively; developing the Sentinel Network for drug safety; and spearheading CDER efforts on patient-focused drug development.

In 2004, Dr. Woodcock became the FDA’s Deputy Commissioner and Chief Medical Officer. Later she took on other executive leadership positions in the Commissioner’s Office, including Deputy Commissioner for Operations and Chief Operating Officer.

In 2007, Dr. Woodcock returned as Director of CDER until she was asked to be the therapeutics lead for “Operation Warp Speed” in early 2020. This entailed supporting the development, evaluation, and availability of treatments such as monoclonal antibodies and antiviral drugs for patients with COVID-19.